LDBIO DIAGNOSTICS : revenue, balance sheet and financial ratios

LDBIO DIAGNOSTICS is a French company founded 28 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in LYON (69009), this company of category PME shows in 2023 a revenue of 3.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - LDBIO DIAGNOSTICS (SIREN 418486353)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue N/C 3 431 943 € 2 681 433 € N/C 2 094 648 € 2 292 934 € 2 000 512 € 1 892 928 € N/C
Net income 1 254 700 € 867 725 € 627 191 € 556 932 € 358 055 € 564 126 € 521 249 € 485 291 € 356 886 €
EBITDA N/C 1 438 515 € 1 003 447 € N/C 520 034 € 705 933 € 608 716 € 632 847 € N/C
Net margin N/C 25.3% 23.4% N/C 17.1% 24.6% 26.1% 25.6% N/C

Revenue and income statement

In 2024, LDBIO DIAGNOSTICS generates positive net income of 1.3 M€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 357 k€ -> 1.3 M€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

1 254 700 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 11%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 79%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

11.346%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

79.172%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

40.2%

Solvency indicators evolution
LDBIO DIAGNOSTICS

Sector positioning

Debt ratio
11.35 2024
2022
2023
2024
Q1: 0.0
Med: 5.92
Q3: 43.75
Average

In 2024, the debt ratio of LDBIO DIAGNOSTICS (11.35) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
79.17% 2024
2022
2023
2024
Q1: 28.05%
Med: 51.52%
Q3: 72.2%
Excellent

In 2024, the financial autonomy of LDBIO DIAGNOSTICS (79.2%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.21 years 2023
2022
2023
Q1: 0.0 years
Med: 0.0 years
Q3: 1.13 years
Average

In 2023, the repayment capacity of LDBIO DIAGNOSTICS (0.21) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 722.47. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

722.466

Liquidity indicators evolution
LDBIO DIAGNOSTICS

Sector positioning

Liquidity ratio
722.47 2024
2022
2023
2024
Q1: 120.09
Med: 209.86
Q3: 363.93
Excellent

In 2024, the liquidity ratio of LDBIO DIAGNOSTICS (722.47) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
1.62x 2023
2022
2023
Q1: 0.0x
Med: 1.61x
Q3: 10.55x
Good

In 2023, the interest coverage of LDBIO DIAGNOSTICS (1.6x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
LDBIO DIAGNOSTICS

Positioning of LDBIO DIAGNOSTICS in its sector

Comparison with sector Fabrication de préparations pharmaceutiques

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 250 336€ to 769 437€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2024
Indicative
250k€ 565k€ 769k€
565 187 € Range: 250 336€ - 769 437€
NAF 5 all-time
How is this estimate calculated?

This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fabrication de préparations pharmaceutiques)

Compare LDBIO DIAGNOSTICS with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques

Frequently asked questions about LDBIO DIAGNOSTICS

What is the revenue of LDBIO DIAGNOSTICS ?

The revenue of LDBIO DIAGNOSTICS in 2023 is 3.4 M€.

Is LDBIO DIAGNOSTICS profitable?

Yes, LDBIO DIAGNOSTICS generated a net profit of 1.3 M€ in 2024.

Where is the headquarters of LDBIO DIAGNOSTICS ?

The headquarters of LDBIO DIAGNOSTICS is located in LYON (69009), in the department Rhone.

Where to find the tax return of LDBIO DIAGNOSTICS ?

The tax return of LDBIO DIAGNOSTICS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does LDBIO DIAGNOSTICS operate?

LDBIO DIAGNOSTICS operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.